Invention Grant
- Patent Title: Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
-
Application No.: US14777888Application Date: 2014-03-21
-
Publication No.: US09724354B2Publication Date: 2017-08-08
- Inventor: Rachael L. Brake , Huifeng Niu
- Applicant: Millennium Pharmaceuticals, Inc.
- Applicant Address: US MA Cambridge
- Assignee: Millennium Pharmaceuticals, Inc.
- Current Assignee: Millennium Pharmaceuticals, Inc.
- Current Assignee Address: US MA Cambridge
- Agency: Choate, Hall & Stewart LLP
- Agent Brenda Herschbach Jarrell
- International Application: PCT/US2014/031442 WO 20140321
- International Announcement: WO2014/153509 WO 20140925
- Main IPC: A01N43/00
- IPC: A01N43/00 ; A61K31/55 ; A61K31/519 ; A61K45/06
Abstract:
Disclosed are methods for the treatment of proliferative disorders. Disclosed in particular, are methods for treatment of proliferative disorders such as cancer, by administering an mTORC1/2 inhibitor in combination with a selective inhibitor of Aurora A kinase. Preferred MTORC1/2 inhibitors include MLN0128 and the preferred Aurora A kinase inhibitor of the combination is MLN8237.
Public/Granted literature
- US20160271140A1 COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE Public/Granted day:2016-09-22
Information query
IPC分类:
